This week in industry news, Novonesis reported strong growth with 8% organic sales and a 36.1% adjusted EBITDA margin, driven by innovation in biosolutions. Meanwhile, the physician-developed brand Resbiotic launched its ResM GLP-1 Postbiotic supplement to support gut health and metabolism. In other updates, Sequential Skin and AMILI secured funding for gut-skin axis research, while the China International Health & Nutrition Expo (NHNE) gears up for its 10th anniversary.
